Production (Stage)
AnaptysBio, Inc.
ANAB
$20.44
-$0.30-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -80.54% | 33.69% | 29.59% | -6.20% | -4.09% |
| Total Depreciation and Amortization | 0.83% | 0.84% | 0.17% | -1.65% | 0.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.78% | 10.70% | 31.31% | 18.84% | 35.96% |
| Change in Net Operating Assets | 103.58% | -6,191.67% | -87.06% | 217.85% | -178.58% |
| Cash from Operations | 83.95% | -560.77% | 52.68% | 42.76% | -8.45% |
| Capital Expenditure | 86.69% | -651.43% | -6.06% | -22.22% | 90.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 151.08% | -149.67% | 2,534.83% | -103.51% | 38.79% |
| Cash from Investing | 150.51% | -150.15% | 2,500.49% | -103.56% | 39.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -47.75% | -99.44% | 9,960.98% | 20.72% | 207.20% |
| Repurchase of Common Stock | -870.18% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -189.03% | 200.74% | -166.65% | 383.24% | -166.35% |
| Cash from Financing | -203.71% | -61.30% | 70.04% | 407.27% | -164.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 64.32% | -157.20% | 560.71% | 2.23% | 83.35% |